Currently, the development of FGS in HNSCC focuses mainly on two approaches: passive targeting with indocyanine green (ICG) [10, 11] or active targeting through anti-EGFR antibodies such as cetuximab and panitumumab [12, 13, 15, 16]. Here, EGFR is linked to head and neck squamous cell carcinoma.